Launch of New Advanced Breast Cancer (ABC) Global Charter

Food and Healthcare Press Releases Tuesday October 31, 2017 08:01
LISBON, Portugal--31 Oct--PRNewswire/InfoQuest
A multi-stakeholder initiative setting out 10 goals to change the future of advanced breast cancer by 2025

The Advanced Breast Cancer (ABC) Global Alliance has launched the ABC Global Charter[i] , a bold new initiative setting out 10 clear goals to drive global improvements in ABC care and survival by 2025. The ABC Global Charter addresses the most urgent and actionable gaps in the treatment and care of patients with ABC to ultimately improve and extend their lives. The ABC Global Alliance, a European School of Oncology backed, multi-stakeholder platform initiated in 2016, will push forward the ABC Global Charter encouraging the worldwide breast cancer community, policy makers and the public to unite to help change the future of ABC patients.

(Logo: http://mma.prnewswire.com/media/591998/ABC_Global_Alliance_Logo.jpg )

Much progress has been made in the diagnosis, management and outcomes of early breast cancer, however major gaps still exist in the treatment and management of ABC and median survival has remained stubbornly stuck at two to three years after diagnosis, with 50% of cases and 58% of deaths occurring in less developed countries.

"The care of ABC has lagged behind that of early breast cancer with too many people still dying too early and change is urgently needed", comments Fatima Cardoso, director of the Breast Unit, Champalimaud Clinical Centre, Lisbon, Portugal and Chair of the ABC Global Alliance. "The ABC Global Charter is an ambitious charter for change. Our goal is to unite the ABC community to work together towards common, achievable goals at international and local levels."

The Charter centres on 10 Actions for Change addressing gaps in ABC research, ABC patient care and ABC in society as identified by the Global Status of Advanced/Metastatic Breast Cancer: 2005-2015 Decade Report[ii] which led to the preliminary mBC Vision 2025 'Call-to-Action'.

The 10 Actions for Change:
1. Double median overall survival for patients with ABC to at least 4 years by 2025
2. Improve quality of life for ABC patients in clinical practice
3. Improve availability of robust epidemiology and outcomes data for ABC

4. Increase availability and access to multidisciplinary care, including palliative, supportive, and psychosocial assistance for patients, families, and caregivers to ensure patients are receiving the best treatment experience

5. Strive for all patients with ABC to have financial support for treatment, care and assistance if unable to work
6. Offer communication skills training to all healthcare providers
7. Provide accurate and up-to-date ABC-specific information tools to all patients who want them
8. Increase public understanding of ABC
9. Improve access to non-clinical supportive services for ABC
10. Protect workforce rights for patients with ABC
The Actions for Change will be discussed in detail at the first ABC Global Alliance meeting on 4-5 November 2017 in Lisbon which follows the ABC4 Conference.
For more details see www.abcglobalalliance.org
References
i. ABC Global Charter.http://www.abcglobalalliance.org/abc-global-alliance-charter/
ii. Pfizer Inc. Global Status of Advanced/Metastatic Breast Cancer: 2005-2015 Decade Report. http://breastcancervision.com . Published March 2016 Accessed [March 2017]
Roberta Ventura
Managing Coordinator ABC Global Alliance
Telephone: +41-91-820-0957
Email: rventura@eso.net
Source: ABC Global Alliance

Latest Press Release

Merck and Pfizer Provide Update on Phase III JAVELIN Lung 200 Trial of Avelumab Monotherapy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer

Merck and Pfizer Inc. (NYSE: PFE) today announced results from the Phase III JAVELIN Lung 200 trial comparing avelumab* to docetaxel in patients with unresectable, recurrent or metastatic non-small cell lung cancer (NSCLC) whose disease progressed after...

PharmaMar Licenses Fully Synthetic Marine-derived Payloads to Seattle Genetics for Use in Drug Conjugates

PharmaMar (MCE: PHM) has announced today the signing of an exclusive licensing agreement with Seattle Genetics Inc. (SGEN: NASDAQ GS) under which Seattle Genetics receives exclusive worldwide rights to certain PharmaMar proprietary molecules for the...

After multiple failed procedures at other medical institutions, Colorado man successfully treated for Atrial Fibrillation at Texas Cardiac Arrhythmia Institute at St. David#s Medical Center

"I was thinking I was on top of the world," Wiseman said. "I was keeping myself in shape. I was taking care of myself mentally and physically. My relationship was solid." Then, during a routine medical exam while serving in the military in California,...

World#s Leading Health Organizations Release Third Edition of Widely Used Resource on Family Planning

Global Handbook Gives Health-Care Providers Accurate and Practical Guidance for Counseling Clients Family planning is considered a development "best buy" and a life-saving intervention for millions of women and girls. Crucial to the success of family...

ไฟเซอร์ ประเทศไทย สนับสนุนงานประชุมวิชาการด้านโรคมะเร็ง

แผนกมะเร็งวิทยาของบริษัท ไฟเซอร์ (ประเทศไทย) จำกัด (Pfizer Oncology) ให้การสนับสนุนการจัดงานประชุมวิชาการ 'The 5th Ramathibodi-Mayo Clinic Joint Conference: Best Practice in Oncology 2018' ช่วง Lunch Symposium' ในหัวข้อ Continuum of care for ALK positive...

Related Topics